StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company's stock.
Nymox Pharmaceutical Stock Performance
Shares of NASDAQ NYMX opened at $0.42 on Friday. Nymox Pharmaceutical has a fifty-two week low of $0.19 and a fifty-two week high of $2.10. The company has a market cap of $37.57 million, a PE ratio of -4.15 and a beta of 0.62. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.38.
Get
Nymox Pharmaceutical alerts:
Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.
Institutional Trading of Nymox Pharmaceutical
A hedge fund recently bought a new stake in Nymox Pharmaceutical stock. Citigroup Inc. bought a new position in shares of Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 109,079 shares of the biopharmaceutical company's stock, valued at approximately $137,000. Citigroup Inc. owned approximately 0.12% of Nymox Pharmaceutical at the end of the most recent quarter. 0.78% of the stock is currently owned by hedge funds and other institutional investors.
About Nymox Pharmaceutical
(Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com承擔了對以下股票的報道尼莫克斯製藥(納斯達克:NYMX-GET Rating)在週日上午發佈的一份報告中。該公司對這家生物製藥公司的股票發佈了賣出評級。
Nymox製藥類股表現
上週五,納斯達克紐約證交所的股價開盤報0.42美元。Nymox Pharmtics的股價為0.19美元,為52周低點,52周高點為2.10美元。該公司市值為3757萬美元,本益比為-4.15,貝塔係數為0.62。該業務的50日簡單移動均線切入位在0.36美元,200日簡單移動均線切入位在0.38美元。
到達
尼莫克斯製藥公司警報:
紐約莫克斯製藥公司(納斯達克代碼:NYMX-GET Rating)最近一次發佈季度收益報告是在11月14日星期一。這家生物製藥公司公佈了本季度每股收益(EPS)(0.02美元)。
Nymox製藥公司的機構交易
一家對沖基金最近購買了Nymox製藥公司的新股。根據花旗集團向美國證券交易委員會提交的最新的Form 13F檔案,花旗集團在第一季度購買了紐約醫藥公司(Nymox Pharmtics Co.)的新股票頭寸(代碼:NYMX-GET Rating)。該機構投資者買入了這家生物製藥公司109,079股股票,價值約13.7萬美元。截至最近一個季度末,花旗集團持有Nymox Pharmtics約0.12%的股份。該股目前由對沖基金和其他機構投資者持有0.78%的股份。
Nymox製藥公司簡介
(獲取評級)
Nymox製藥公司是一家生物製藥公司,在加拿大、美國、歐洲和國際上從事老齡人口藥物的研究和開發。它的主要候選藥物是Fexapbon Trifltate(NX-1207),它已經完成了治療良性前列腺增生症的第三階段臨床試驗,以及治療低級別侷限性前列腺癌的第二階段臨床試驗,以及肝細胞癌的臨床前研究。
專題報道
- 免費獲取StockNews.com關於NYMOX製藥公司(NYMX)的研究報告
- 好時為什麼是一隻甜蜜的衰退股票
- 亞馬遜股票是否會在2023年為投資者提供服務?
- 分析師將貨運情緒轉回遠期
- 各機構預訂波音航班
- 兩家生物技術公司在其流水線中以單一產品掀起波瀾
獲得Nymox藥學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nymox製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。